Combining 5-Fluorouracil and CB3717 for Colorectal Cancer
Author Information
Author(s): B.M.J. Cantwell, A.L. Harris
Primary Institution: University Department of Clinical Oncology, Regional Radiotherapy Centre, Newcastle General Hospital
Hypothesis
Combining 5-fluorouracil with CB3717 will enhance treatment efficacy in colorectal adenocarcinoma.
Conclusion
The combination of 5-fluorouracil and CB3717 did not show any objective responses in patients with colorectal cancer.
Supporting Evidence
- No objective responses were observed in the study.
- Two patients had some improvement in symptoms but no significant tumor regression.
- Eight patients experienced moderate to severe malaise after treatment.
- Ten patients had mild nausea after treatment.
- Myelosuppression was not detected in any patient.
Takeaway
Doctors tried a new medicine with a common cancer drug to help patients, but it didn't work as they hoped.
Methodology
Twelve chemotherapy-naive patients were treated with CB3717 and 5-fluorouracil, with assessments of response and side effects.
Limitations
The study had a small sample size and no objective responses were observed.
Participant Demographics
Median age was 55 years, with a range of 35-70 years; most had liver metastases.
Statistical Information
Confidence Interval
0%-26.4%
Want to read the original?
Access the complete publication on the publisher's website